Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biosense Webster, Inc.
Benefits of Catheter Ablation with the NAVISTAR® THERMOCOOL® Catheter Sustained for One Year in the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation
June 6th, 2009
In final, one-year results of a multicenter randomized clinical study, catheter ablation demonstrated significantly better outcomes compared to anti-arrhythmic drug (AAD) therapy for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation. Atrial fibrillation, or AFib as it is more commonly referred to, is the most prevalent cardiac arrhythmia (heart rhythm disorder), affecting an estimated 20 million people worldwide. It is also one of the most common causes of stroke. In a presentation here today during the Late Breaking Clinical Trials session at Heart Rhythm 2009, patients receiving cardiac ablation with the NAVISTAR® THERMOCOOL®...
Source: Law & Health Weekly (2009-06-06)
|
